Ampersand Capital Partners, a private equity firm specializing in growth investments in the life sciences and healthcare sectors, announces its acquisition of Purna Pharmaceuticals, a trusted provider of development and manufacturing services for liquid and semi-solid dosage forms in support of pharmaceutical industry customers. As part of Ampersand’s broader life sciences portfolio, the investment creates opportunities for strategic collaboration between Purna and MedPharm, Ampersand’s topical and transdermal pharmaceutical development and manufacturing services platform.
Read the full article: Ampersand Capital Partners Acquires Purna Pharmaceuticals //
Source: https://www.globenewswire.com/news-release/2026/02/12/3237059/0/en/Ampersand-Capital-Partners-Acquires-Purna-Pharmaceuticals.html